Publication

When More Isn’t Merrier: Pharmaceutical Alliance Networks and Breakthrough Innovation

Dong, J. Q. & McCarthy, K. J., Mar-2019, In : Drug Discovery Today. 24, 3, p. 673-677

Research output: Contribution to journalArticleAcademicpeer-review

APA

Dong, J. Q., & McCarthy, K. J. (2019). When More Isn’t Merrier: Pharmaceutical Alliance Networks and Breakthrough Innovation. Drug Discovery Today, 24(3), 673-677. https://doi.org/10.1016/j.drudis.2019.01.002

Author

Dong, John Qi ; McCarthy, Killian J. / When More Isn’t Merrier : Pharmaceutical Alliance Networks and Breakthrough Innovation. In: Drug Discovery Today. 2019 ; Vol. 24, No. 3. pp. 673-677.

Harvard

Dong, JQ & McCarthy, KJ 2019, 'When More Isn’t Merrier: Pharmaceutical Alliance Networks and Breakthrough Innovation' Drug Discovery Today, vol. 24, no. 3, pp. 673-677. https://doi.org/10.1016/j.drudis.2019.01.002

Standard

When More Isn’t Merrier : Pharmaceutical Alliance Networks and Breakthrough Innovation. / Dong, John Qi; McCarthy, Killian J.

In: Drug Discovery Today, Vol. 24, No. 3, 03.2019, p. 673-677.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Dong JQ, McCarthy KJ. When More Isn’t Merrier: Pharmaceutical Alliance Networks and Breakthrough Innovation. Drug Discovery Today. 2019 Mar;24(3):673-677. https://doi.org/10.1016/j.drudis.2019.01.002


BibTeX

@article{91d3b732598b4f568cadffbbedbfb266,
title = "When More Isn’t Merrier: Pharmaceutical Alliance Networks and Breakthrough Innovation",
abstract = "Strategic alliances, in particular strategic alliances with universities, are widely thought to be beneficial to the drug discovery process. However, the discussion of alliances and their effect has tended to focus on single alliances and has ignored the fact that firms tend to participate in multiple alliances simultaneously. Here, we show the importance of adopting a portfolio perspective of strategic alliances. We build a model of the U.S. pharmaceutical industry, and show how 2298 alliances, announced over a 15-year period, impact the alliance portfolios of 324 pharmaceutical firms, and how that, in turn, impacts the breakthrough innovations that these firms produce. In doing so, we show the stengths and benifits of strategic alliances, but we also show the dangers of adopting a more the merrier approach to strategic alliance making.",
keywords = "DRUG DISCOVERY, STRATEGIC ALLIANCES, COLLABORATION",
author = "Dong, {John Qi} and McCarthy, {Killian J.}",
year = "2019",
month = "3",
doi = "10.1016/j.drudis.2019.01.002",
language = "English",
volume = "24",
pages = "673--677",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "ELSEVIER SCI LTD",
number = "3",

}

RIS

TY - JOUR

T1 - When More Isn’t Merrier

T2 - Pharmaceutical Alliance Networks and Breakthrough Innovation

AU - Dong, John Qi

AU - McCarthy, Killian J.

PY - 2019/3

Y1 - 2019/3

N2 - Strategic alliances, in particular strategic alliances with universities, are widely thought to be beneficial to the drug discovery process. However, the discussion of alliances and their effect has tended to focus on single alliances and has ignored the fact that firms tend to participate in multiple alliances simultaneously. Here, we show the importance of adopting a portfolio perspective of strategic alliances. We build a model of the U.S. pharmaceutical industry, and show how 2298 alliances, announced over a 15-year period, impact the alliance portfolios of 324 pharmaceutical firms, and how that, in turn, impacts the breakthrough innovations that these firms produce. In doing so, we show the stengths and benifits of strategic alliances, but we also show the dangers of adopting a more the merrier approach to strategic alliance making.

AB - Strategic alliances, in particular strategic alliances with universities, are widely thought to be beneficial to the drug discovery process. However, the discussion of alliances and their effect has tended to focus on single alliances and has ignored the fact that firms tend to participate in multiple alliances simultaneously. Here, we show the importance of adopting a portfolio perspective of strategic alliances. We build a model of the U.S. pharmaceutical industry, and show how 2298 alliances, announced over a 15-year period, impact the alliance portfolios of 324 pharmaceutical firms, and how that, in turn, impacts the breakthrough innovations that these firms produce. In doing so, we show the stengths and benifits of strategic alliances, but we also show the dangers of adopting a more the merrier approach to strategic alliance making.

KW - DRUG DISCOVERY

KW - STRATEGIC ALLIANCES

KW - COLLABORATION

U2 - 10.1016/j.drudis.2019.01.002

DO - 10.1016/j.drudis.2019.01.002

M3 - Article

VL - 24

SP - 673

EP - 677

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 3

ER -

ID: 73709817